Abstract
Adoptive immunotherapy with donor-derived buffy coat cells for relapsed hematological malignancies after allogeneic BMT is an established and highly effective treatment. We report a patient who relapsed on day +330 after allogeneic sibling BMT for multiple myeloma with multiple solid subcutaneous tumors consisting of plasma cells. Histology and immunocytology of the bone marrow did not show plasma cell infiltration. After cessation of the immunosuppression consisting of cyclosporine and methylprednisolone, a total of 6.2 × 107/kg recipient body weight CD3+ T cells derived from the donor by leukapheresis were transfused on 4 consecutive days. To enhance the T cell effect six doses of 5 million units alpha interferon were given subcutaneously. Five days later the tumors started to shrink and have completely vanished since day ×400 after BMT. The patient developed acute GVHD grade III of the liver and gut which was treated by reinduction of various immunosuppressive drugs. Up to now there is no evidence for relapse of the multiple myeloma, but the patient suffers from extensive chronic GVHD (gut and liver). This is the first report to demonstrate a graft-versus-myeloma effect for relapse with solid tumor manifestation after sibling BMT with donor-derived buffy coat cells as adoptive immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bertz, H., Burger, J., Kunzmann, R. et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11, 281–283 (1997). https://doi.org/10.1038/sj.leu.2400546
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400546
Keywords
This article is cited by
-
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
Bone Marrow Transplantation (2008)
-
T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
Bone Marrow Transplantation (2007)
-
Mini–Midi–Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation
Leukemia (2007)
-
The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma
Leukemia (2006)
-
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma
Bone Marrow Transplantation (2005)